Ms. Davies said the study focused on the two most commonly prescribed doses in the U.K. and that these were the two most disparate doses that allowed a workable analysis. “It’s become more common in the U.K. in more recent years to prescribe a 10 mg dose,” she said, “and I’d like to repeat this analysis looking at that group of patients.”
Thomas R. Collins is a freelance writer living in South Florida.
ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE
References
- Fleischmann R, Mysler E, Hall S, et al. Efficacy and safety of tofacitinib monotherapy, tofacitinib with methotrexate, and adalimumab with methotrexate in patients with rheumatoid arthritis (ORAL Strategy): A phase 3B/4, double-blind, head-to-head, randomised controlled trial. Lancet. 2017 Jun 15. pii: S0140–6736(17)31618-5. [Epub ahead of print]
- Taylor P, Keystone E, van der Heijde D, et al. Baricitinib versus placebo or adalimumab in rheumatoid arthritis. N Engl J Med. 2017 Feb 16;376(7):652–662.
- Davies R, Lunt M, Barton A, et al. The effect of a low versus high first prescribed dose of methotrexate on EULAR response at six months using data from the RAMS study (abstract OP0225). Annual European Congress of Rheumatology. 2017 Jun 15. Madrid, Spain.
